NEW YORK – ArcherDx said on Friday that it has signed a non-exclusive, multiyear partnership with Illumina intended to broaden access to next-generation sequencing oncology testing, including — upon regulatory approval — companion diagnostics for therapeutic selection, personalized monitoring, and new recurrence surveillance in vitro diagnostics.